FDA Approves Gilteritinib for FLT3+ AML

November 28, 2018 – The FDA has approved gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML). The approval of the FLT3 inhibitor was based on data from the ADMIRAL study, in which 138 adult patients with FLT3-positive relapsed/refractory AML received gilteritinib orally at 120 mg daily. The rate of complete remission (CR) or CR with partial hematologic recovery … (leggi tutto)